A New First-Line Treatment Regimen for H. pylori Infection

Phase III trial findings are reported for a recently approved rifabutin-based triple therapy.

Treatment of Helicobacter pylori infection is decreasingly successful using standard treatment regimens due to increasing antibiotic resistance. Specifically, the rapidly rising resistance of H. pylori to clarithromycin, levofloxacin, and metronidazole has led to recommendations against the empirical use of these drugs as part of combination therapies. Now, investigators report efficacy and safety findings for a novel rifabutin-based regimen, which was recently approved by the FDA for H. pylori treatment in adults.

In this industry-funded, phase III trial conducted in the U.S., 455 H. pylori-treatment–naive patients with dyspepsia and a confirmed H. pylori diagnosis were randomized to treatment with capsules containing rifabutin, amoxicillin…

Reviewing Author

John R. Saltzman, MD

Disclosures

Consultant/Advisory BoardIterative Scopes

Editorial BoardsGastrointestinal Endoscopy; UpToDate

Leadership Positions in Professional SocietiesAmerican College of Gastroenterology (Trustee)

OtherVice President of Medical Affairs, 1Globe Health Institute